4 D Molecular Therapeutics Inc (FDMT)

Nov 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2025

Nov 21, 2025

Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - MarketScreener

Nov 21, 2025

Nov 21, 2025

4D Molecular Therapeutics taps Kristian Humer as CFO - MSN

Nov 21, 2025

Nov 20, 2025

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat

Nov 20, 2025

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat

Nov 20, 2025

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan

Nov 20, 2025

Nov 19, 2025

4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada

Nov 19, 2025

Nov 19, 2025

[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

Nov 19, 2025

4D Molecular Therapeutics Executive Sells Shares - TradingView

Nov 19, 2025

Nov 19, 2025

Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView

Nov 19, 2025

Nov 19, 2025

Published on: 2025-11-19 17:30:27 - newser.com

Nov 19, 2025

Nov 18, 2025

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Nov 18, 2025

Nov 18, 2025

4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN

Nov 18, 2025

Nov 18, 2025

What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com

Nov 18, 2025

Nov 18, 2025

FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView

Nov 18, 2025

Nov 18, 2025

FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView

Nov 18, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks

Nov 17, 2025

Nov 17, 2025

4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus

Nov 17, 2025

Nov 17, 2025

4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints New CFO - TradingView

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative

Nov 17, 2025

Nov 17, 2025

[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics (Nasdaq: FDMT) names Kristian Humer CFO to lead finance - Stock Titan

Nov 17, 2025

Nov 16, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat

Nov 16, 2025

Nov 15, 2025

4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 15, 2025

Nov 15, 2025

HC Wainwright Has Optimistic Outlook of FDMT FY2026 Earnings - MarketBeat

Nov 15, 2025

Nov 14, 2025

Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com

Nov 14, 2025

Nov 14, 2025

4DMT Announces New Employment Inducement Grants - Enidnews.com

Nov 14, 2025

Nov 14, 2025

4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan

Nov 14, 2025

Nov 14, 2025

Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat

Nov 14, 2025

Nov 12, 2025

Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks

Nov 12, 2025

Nov 12, 2025

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st

Nov 12, 2025

Nov 12, 2025

Royal Bank Of Canada Issues Positive Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat

Nov 12, 2025

Nov 11, 2025

Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq

Nov 11, 2025

Nov 11, 2025

Working capital per share of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView

Nov 11, 2025

Nov 11, 2025

4D Molecular Therapeutics Misses On Revenue But Secures New Funding - Finimize

Nov 11, 2025

Nov 11, 2025

4D Molecular Therapeutics: Financial Backing Strengthens Clinical Pipeline Prospects - Ad-hoc-news.de

Nov 11, 2025

Nov 11, 2025

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com

Nov 11, 2025

Nov 10, 2025

4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - TipRanks

Nov 10, 2025

Nov 10, 2025

Can 4D Molecular Therapeutics Inc. stock weather global recessionOptions Play & Daily Profit Focused Stock Screening - newser.com

Nov 10, 2025

Nov 10, 2025

4D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Nov 10, 2025

Nov 10, 2025

4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView

Nov 10, 2025

Nov 10, 2025

[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report | FDMT SEC FilingForm 10-Q - Stock Titan

Nov 10, 2025

Nov 10, 2025

4D Molecular Therapeutics' Q3 revenue misses - TradingView

Nov 10, 2025

Nov 10, 2025

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Nov 10, 2025

Nov 10, 2025

4DMT (NASDAQ: FDMT) signs APAC license for 4D-150: $85M upfront, $50M+ cost sharing - Stock Titan

Nov 10, 2025

Nov 09, 2025

4D Molecular Therapeutics Closes $93.3 Million Stock Offering - The Globe and Mail

Nov 09, 2025

Nov 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to Equal Weight at Morgan Stanley - MarketBeat

Nov 08, 2025

Nov 07, 2025

4D Molecular Therapeutics Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView

Nov 07, 2025